{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:12:11Z","timestamp":1776366731490,"version":"3.51.2"},"reference-count":33,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Immune-mediated colitis (IMC) is a toxicity associated with immune checkpoint inhibitors (ICIs) that is becoming increasingly common. Studies exploring the clinical course and outcomes of IMC have been limited to relatively small sample sizes (&lt;200 patients). We therefore aimed to provide a comprehensive account of the clinical, endoscopic, and histologic features of IMC as well as the efficacy of IMC treatment in a representative sample. <jats:bold>Methods:<\/jats:bold> This was a single-center retrospective study of all patients who received ICIs at our institution between January 2010 and February 2024 and subsequently developed IMC. Detailed information was collected from the electronic health record regarding patient demographics and IMC stool biomarkers, endoscopic and histologic reports, clinical symptoms and treatment, and outcomes such as clinical symptom remission, hospitalization, and mortality. <jats:bold>Results:<\/jats:bold> A total of 1,151 patients were included. Patients commonly presented with diarrhea (98.3%) or abdominal pain (38.6%). Selective immunosuppressive therapy was needed in approximately 46% of patients, and 85% achieved symptom remission. Among patients with macroscopic inflammation on endoscopy, 250 (57.6%) had nonulcerative findings, whereas 139 (32.0%) had ulceration. Among patients with histologic inflammation, approximately 60% had acute inflammation, 28% had chronic inflammation, and 12% had microscopic inflammation. Infliximab was associated with a shorter time to clinical response and required fewer doses than vedolizumab, with comparable efficacy between the 2 treatments. <jats:bold>Conclusions:<\/jats:bold> Our study represents the largest to date exploring the various manifestations of IMC, along with associated treatment approaches and outcomes. We found that its features overlap with those of different inflammatory colitides. Both infliximab and vedolizumab were equally effective in achieving symptom remission; however, infliximab was associated with a shorter time to response. As the number of patients affected by IMC continues to grow, larger-scale studies will be essential to validate and expand upon these findings.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7046","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:39Z","timestamp":1757507139000},"source":"Crossref","is-referenced-by-count":2,"title":["Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options"],"prefix":"10.6004","volume":"23","author":[{"given":"Malek","family":"Shatila","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Colli","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takigawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres Caleb","family":"Urias Rivera","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Abdul-Baki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanvi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Baerman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene Jeong-Ah","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raakhi","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Vemulapalli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Natha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Salim","sequence":"additional","affiliation":[{"name":"The Memorial Hermann Texas Medical Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnavathana","family":"Varatharajalu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Stanford Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha Shirwaiker","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Curr Oncol","first-page":"3044","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA,  Immune checkpoint inhibitors in cancer therapy. Curr Oncol 2022;29:3044\u20133060."},{"key":"B2","series-title":"Science","first-page":"1350","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350\u20131355."},{"key":"B3","series-title":"Ann Oncol","first-page":"2375","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo J","year":"2015","unstructured":"Naidoo J, Page D, Li BT,  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375\u20132391."},{"key":"B4","series-title":"J Immunother Cancer","first-page":"95","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih H","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W,  Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95."},{"key":"B5","series-title":"Gastroenterology","first-page":"1384","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan M","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160:1384\u20131393."},{"key":"B6","series-title":"Inflamm Bowel Dis","first-page":"1695","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang Y","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E,  Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695\u20131705."},{"key":"B7","series-title":"Br J Cancer","first-page":"207","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung VTF","year":"2020","unstructured":"Cheung VTF, Gupta T, Olsson-Brown A,  Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020;123:207\u2013215."},{"key":"B8","series-title":"Gastrointest Endosc","first-page":"273","article-title":"Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients","volume":"100","author":"Wang Y","year":"2024","unstructured":"Wang Y, Abu-Sbeih H, Tang T,  Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest Endosc 2024;100:273\u2013282.e4."},{"key":"B9","series-title":"J Immunother Cancer","first-page":"292","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes MS","year":"2019","unstructured":"Hughes MS, Molina GE, Chen ST,  Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292."},{"key":"B10","series-title":"Inflamm Bowel Dis","first-page":"385","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","author":"Choi K","year":"2019","unstructured":"Choi K, Abu-Sbeih H, Samdani R,  Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385\u2013393."},{"key":"B11","series-title":"J Cancer Res Clin Oncol","first-page":"5429","article-title":"Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to immune checkpoint inhibitors","volume":"149","author":"Thomas AR","year":"2023","unstructured":"Thomas AR, Liu C, Tong YT,  Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to immune checkpoint inhibitors. J Cancer Res Clin Oncol 2023;149:5429\u20135436."},{"key":"B12","series-title":"Am J Surg Pathol","first-page":"643","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen JH","year":"2017","unstructured":"Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 2017;41:643\u2013654."},{"key":"B13","series-title":"J Natl Compr Canc Netw","first-page":"700","article-title":"Association of chronic immune-mediated diarrhea and colitis with favorable cancer response","volume":"19","author":"Zou F","year":"2020","unstructured":"Zou F, Abu-Sbeih H, Ma W,  Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. J Natl Compr Canc Netw 2020;19:700\u2013708."},{"key":"B14","series-title":"JCO Oncol Pract","first-page":"453","article-title":"Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review","volume":"16","author":"Gong Z","year":"2020","unstructured":"Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 2020;16:453\u2013461."},{"key":"B15","series-title":"J Immunother Cancer","first-page":"e007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran YR","year":"2023","unstructured":"Badran YR, Zou F, Durbin SM,  Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother Cancer 2023;11:e007195."},{"key":"B16","series-title":"J Immunother Cancer","first-page":"e003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou F","year":"2021","unstructured":"Zou F, Faleck D, Thomas A,  Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 2021;9:e003277."},{"key":"B17","series-title":"Am J Gastroenterol","first-page":"1679","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Shirwaikar Thomas A","year":"2023","unstructured":"Shirwaikar Thomas A, Lee SE, Shatila M,  IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience. Am J Gastroenterol 2023;118:1679\u20131683."},{"key":"B18","series-title":"Gastroenterology","first-page":"932","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu S","year":"2021","unstructured":"Bishu S, Melia J, Sharfman W,  Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology 2021;160:932\u2013934.e3."},{"key":"B19","series-title":"J Immunother Cancer","first-page":"e005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem RB","year":"2022","unstructured":"Holmstroem RB, Nielsen OH, Jacobsen S,  COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer 2022;10:e005111."},{"key":"B20","series-title":"Sci Transl Med","first-page":"eabq4006","article-title":"Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor\u2013induced colitis","volume":"15","author":"Halsey TM","year":"2023","unstructured":"Halsey TM, Thomas AS, Hayase T,  Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor\u2013induced colitis. Sci Transl Med 2023;15:eabq4006."},{"key":"B21","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Accessed March 10, 2024. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"B22","series-title":"Cancer Treat Rev","first-page":"102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen DL","year":"2022","unstructured":"Nielsen DL, Juhl CB, Chen IM,  Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis. Cancer Treat Rev 2022;109:102440."},{"key":"B23","series-title":"J Immunother","first-page":"325","article-title":"Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies","volume":"44","author":"Tran AN","year":"2021","unstructured":"Tran AN, Wang M, Hundt M,  Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies. J Immunother 2021;44:325\u2013334."},{"key":"B24","series-title":"Oncoimmunology","first-page":"e1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang DY","year":"2017","unstructured":"Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805."},{"key":"B25","series-title":"Gastrointest Endosc","first-page":"273","article-title":"Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients","volume":"100","author":"Wang Y","year":"2024","unstructured":"Wang Y, Abu-Sbeih H, Tang T,  Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest Endosc 2024;100:273\u2013282.e4."},{"key":"B26","series-title":"Clin Gastroenterol Hepatol","first-page":"878","article-title":"Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease","volume":"21","author":"Shirwaikar Thomas A","year":"2023","unstructured":"Shirwaikar Thomas A, Hanauer S, Wang Y. Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease. Clin Gastroenterol Hepatol 2023;21:878\u2013890."},{"key":"B27","series-title":"J Clin Oncol","first-page":"4073","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD,  Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39:4073\u20134126."},{"key":"B28","series-title":"J Immunother Cancer","first-page":"e002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer JR","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA,  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435."},{"key":"B29","series-title":"Aliment Pharmacol Ther","first-page":"1432","article-title":"Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis","volume":"52","author":"Ibraheim H","year":"2020","unstructured":"Ibraheim H, Baillie S, Samaan MA,  Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432\u20131452."},{"key":"B30","series-title":"Aliment Pharmacol Ther","first-page":"1370","article-title":"Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis","volume":"56","author":"Dahl EK","year":"2022","unstructured":"Dahl EK, Abed OK, Kjeldsen J,  Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2022;56:1370\u20131382."},{"key":"B31","series-title":"J Immunother Cancer","first-page":"142","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih H","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D,  Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018;6:142."},{"key":"B32","series-title":"J Clin Oncol","first-page":"2517","article-title":"Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis","volume":"42","author":"Shatila M","year":"2024","unstructured":"Shatila M, Varatharajalu K, Shen SE,  Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis. J Clin Oncol 2024;42(Suppl):Abstract 2517."},{"key":"B33","series-title":"J Clin Oncol","first-page":"2660","article-title":"First-line treatment of fecal microbiota transplantation for immune-mediated colitis","volume":"42","author":"Varatharajalu K","year":"2024","unstructured":"Varatharajalu K, Shatila M, Campbell MT,  First-line treatment of fecal microbiota transplantation for immune-mediated colitis. J Clin Oncol 2024;42(Suppl):Abstract 2660."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-e257046.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-e257046.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-e257046.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:39Z","timestamp":1757507139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-e257046.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7046","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}